< Back to previous page
Researcher
Ewout Landeloos
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Oncology
Affiliations
- Department of Oncology (Department)
Member
From22 Aug 2022 → Today - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From6 Aug 2018 → 5 Aug 2022 - Marine Lab (Research group)
Member
From6 Aug 2018 → 5 Aug 2022
Publications
1 - 10 of 11
See also Ewout Landeloos for publications of Flanders Institute for Biotechnology.
Here below the publications of KU Leuven.
- Transcriptomic characterization of the melanoma ecosystem before and early during immune checkpoint inhibition(2024)
- A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma(2024)Published in: CellISSN: 0092-8674Issue: 1Volume: 187
- SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response(2022)Published in: OncoImmunologyISSN: 2162-402XIssue: 1Volume: 11
- A cellular hierarchy in melanoma uncouples growth and metastasis (vol 610, pg 190, 2022)(2022)Published in: NatureISSN: 0028-0836Issue: 7934Volume: 611Pages: E4 - E4
- A cellular hierarchy in melanoma uncouples growth and metastasis(2022)Published in: NatureISSN: 0028-0836Issue: 7930Volume: 610Pages: 190 - +
- Epithelial-to-mesenchymal-like transition events in melanoma(2022)Published in: FEBS JOURNALISSN: 1742-464XIssue: 5Volume: 289Pages: 1352 - 1368
- Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer(2022)Published in: CANCER IMMUNOLOGY RESEARCHISSN: 2326-6066Issue: 1Volume: 10Pages: 126 - 141
- itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens (vol 66, 103288, 2021)(2021)Published in: EBioMedicineISSN: 2352-3964Volume: 69
- Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial(2021)Published in: EBioMedicineISSN: 2352-3964Volume: 66
- Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin (vol 22, 126, 2021)(2021)Published in: TrialsISSN: 1745-6215Issue: 1Volume: 22Pages: 0 - 0